Orphan Biologics Should Get Two Extra Years Of Exclusivity, NORD Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Organization tells Rep. Waxman it still "wholeheartedly" supports his bill, but is planning its legislative approach around longer brand exclusivity.
You may also be interested in...
NORD Refines Orphan Exclusivity Position
Second letter to Waxman suggests that all orphan biologics should get nine years of exclusivity, noting the "challenge to innovation" posed by untreated rare diseases.
Follow-on Biologics: As Mark-Ups Loom, What's Waxman's End Game?
Coming to an abrupt halt after racing at full speed is never easy, but that seems to be the best play available to generic advocates of a legislative pathway for follow-on biologics
NORD Refines Orphan Exclusivity Position
Second letter to Waxman suggests that all orphan biologics should get nine years of exclusivity, noting the "challenge to innovation" posed by untreated rare diseases.